Merck Calls The Ambulance Squad
Tweet
Share
E-mailGet Alerts MRK Hot Sheet
Price: $129.56 +3.34%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.9%
Revenue Growth %: +3.6%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.9%
Revenue Growth %: +3.6%
Join SI Premium – FREE
CONTRIBUTOR Douglas A. McIntyre http://247wallst.blogspot.com
Things have gotten so bad at Merck (NYSE: MRK) that they are renting ambulances for victims of the company's Vioxx drug and MRK sharesholders.
Merck disclosed yesterday that it was in a dispute over $5.58 billion in taxes it may owe the US and Canada.
Almost any child who reads a newspaper knows that Merck's Vioxx painkiller may cause heart problems and that the company is involved in countless suits that could cost it billions of dollars in damages. And now the taxman cometh.
Merck has $6.2 billion in cash on its balance sheet, so, if it had to pay these taxes, it would not have a great deal left to cover Vioxx judgments, although future earnings could generate more cash.
It is hard to figure out how the tax number could get so high. Merck's revenues are about $22 billion, so it is a pretty big bill.
Merck's shares have recovered from the Vioxx shock. Its stock has recovered from a 52-week low of $27.99 to $45.90, near its high for the period. In 2003, the stock traded at $63.
The tax issue is bound to send the shares lower.
It is hard, almost impossible to believe that Merck was Fortune's Most Admired Company for six years in a row.
How the mighty have fallen.
http://247wallst.blogspot.com
Things have gotten so bad at Merck (NYSE: MRK) that they are renting ambulances for victims of the company's Vioxx drug and MRK sharesholders.
Merck disclosed yesterday that it was in a dispute over $5.58 billion in taxes it may owe the US and Canada.
Almost any child who reads a newspaper knows that Merck's Vioxx painkiller may cause heart problems and that the company is involved in countless suits that could cost it billions of dollars in damages. And now the taxman cometh.
Merck has $6.2 billion in cash on its balance sheet, so, if it had to pay these taxes, it would not have a great deal left to cover Vioxx judgments, although future earnings could generate more cash.
It is hard to figure out how the tax number could get so high. Merck's revenues are about $22 billion, so it is a pretty big bill.
Merck's shares have recovered from the Vioxx shock. Its stock has recovered from a 52-week low of $27.99 to $45.90, near its high for the period. In 2003, the stock traded at $63.
The tax issue is bound to send the shares lower.
It is hard, almost impossible to believe that Merck was Fortune's Most Admired Company for six years in a row.
How the mighty have fallen.
http://247wallst.blogspot.com
You May Also Be Interested In
- Merck (MRK) PT Raised to $155 at Scotiabank
- Merck reaches deal to expand HIV drug access via ADAP programs
- Tesla Q2 deliveries crush forecasts at 480,126, erasing backlog concerns
Create E-mail Alert Related Categories
ContributorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
